Patents by Inventor Michael J. Kosinski
Michael J. Kosinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964023Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.Type: GrantFiled: June 24, 2022Date of Patent: April 23, 2024Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Publication number: 20240108711Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.Type: ApplicationFiled: November 9, 2023Publication date: April 4, 2024Applicant: Merck Sharp & Dohme LLCInventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
-
Patent number: 11850278Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.Type: GrantFiled: July 13, 2021Date of Patent: December 26, 2023Assignee: Merck Sharp & Dohme LLCInventors: William J. Smith, Patrick McHugh, Michael A. Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
-
Patent number: 11759510Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: GrantFiled: June 24, 2022Date of Patent: September 19, 2023Assignee: Merck, Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Patent number: 11759523Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: GrantFiled: June 24, 2022Date of Patent: September 19, 2023Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Patent number: 11759511Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: GrantFiled: June 24, 2022Date of Patent: September 19, 2023Assignee: MERCK SHARP & DOHME LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Publication number: 20230107713Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: September 22, 2022Publication date: April 6, 2023Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
-
Publication number: 20230094548Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: September 27, 2022Publication date: March 30, 2023Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
-
Publication number: 20230075760Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: September 22, 2022Publication date: March 9, 2023Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
-
Publication number: 20230041441Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: September 27, 2022Publication date: February 9, 2023Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
-
Publication number: 20230029424Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: September 27, 2022Publication date: January 26, 2023Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
-
Patent number: 11524076Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.Type: GrantFiled: September 4, 2018Date of Patent: December 13, 2022Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Patrick McHugh, Janelle Konietzko
-
Patent number: 11491216Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: GrantFiled: September 4, 2018Date of Patent: November 8, 2022Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
-
Publication number: 20220323565Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: June 24, 2022Publication date: October 13, 2022Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Publication number: 20220323593Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.Type: ApplicationFiled: June 24, 2022Publication date: October 13, 2022Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Publication number: 20220323564Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: June 24, 2022Publication date: October 13, 2022Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Publication number: 20220323592Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: ApplicationFiled: June 24, 2022Publication date: October 13, 2022Applicant: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Patent number: 11395849Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these N serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.Type: GrantFiled: September 4, 2018Date of Patent: July 26, 2022Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Patent number: 11389540Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.Type: GrantFiled: September 4, 2018Date of Patent: July 19, 2022Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Publication number: 20210379174Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.Type: ApplicationFiled: July 13, 2021Publication date: December 9, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: William J. Smith, Patrick McHugh, Michael A. Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski